Praxis Precision Medicines, Inc. (PRAX)

Praxis Precision Medicines, Inc. stock has experienced significant events, including a 937.99% increase between April 9, 2025, and April 8, 2026, and a 7.3% increase between January 1st, 2026, and April 11, 2026. The company underwent a 1-15 reverse stock split on November 29, 2023. Positive results were reported from the ESSENTIAL3 program for ulixacaltamide in essential tremor in October 2025, and positive topline results were announced from the EMBRAVE Part A trial of elsunersen in April 2026. Ulixacaltamide received Breakthrough Therapy Designation from the FDA in December 2025. Praxis submitted two New Drug Applications (NDAs) in Q1 2026 for ulixacaltamide and relutrigine, with relutrigine's NDA accepted by the FDA and granted priority review. The company reported $926.1 million in cash, equivalents, and marketable securities as of December 31, 2025, and raised an estimated $621.2 million through a public offering in January 2026. Several firms reiterated or initiated optimistic price targets in Q1 2026.

The demand for Praxis Precision Medicines, Inc.'s products and services is not typically subject to seasonality. Demand is primarily driven by the prevalence of the targeted medical conditions, the success of clinical trials, regulatory approvals, and market access, which are generally independent of seasonal fluctuations.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceuticals & Biotech industries. The company utilizes its Cerebrum and Solidus platforms to discover and develop treatments for neurological disorders. Its pipeline includes ulixacaltamide, PRAX-562, PRAX-628, elsunersen, relutrigine, and other programs like PRAX-222, PRAX-020, PRAX-080, PRAX-090 and PRAX-100.

Praxis Precision Medicines, Inc. is headquartered in Boston, Massachusetts, United States. The company conducts preclinical and clinical research primarily in the United States, with clinical trial sites extending across North America and Europe.

Praxis Precision Medicines has maintained a positive brand reputation over the past year, driven by its clinical advancements and positive analyst sentiment. The company has received a consensus "Buy" rating from analysts, with a strong bullish outlook. Positive topline results from the ESSENTIAL3 program for ulixacaltamide in essential tremor in October 2025, Breakthrough Therapy Designations for ulixacaltamide and relutrigine, NDA submissions and priority review for ulixacaltamide and relutrigine, and positive elsunersen trial results have positively affected its reputation.

Praxis Precision Medicines, Inc. stock ownership is primarily institutional, with approximately 105.81% held by institutional shareholders, 50.60% by Praxis Precision Medicines insiders, and 0.00% by retail investors. Other sources indicate institutional ownership around 78.28% to 93.59%, with insiders holding about 8.27% and public companies/individual investors holding 12.48% to 13.45%. Major institutional owners include Janus Henderson Group Plc, BlackRock, Inc., Perceptive Advisors Llc, Vanguard Group Inc, Fmr Llc, Orbis Allan Gray Ltd, Baker Bros. Advisors Lp, Adage Capital Partners Gp, L.l.c., Driehaus Capital Management Llc, Deerfield Management Company, L.p. (series C), State Street Corp., and T. Rowe Price Investment Management Inc. The largest individual shareholder is Bsof Parallel Master Fund LP, owning 4.89 million shares, representing 17.57% of the company.